Io Biotech Posts Wider Loss in Q2

Io Biotech (NASDAQ:IOBT), a clinical-stage oncology company specializing in cancer vaccines, released its second quarter results on August 14, 2025. The most important update was the outcome of the pivotal Phase 3 trial for Cylembio®, its lead cancer vaccine candidate. The study demonstrated a clinical benefit by improving progression free survival in advanced melanoma, but it narrowly missed the statistical significance needed for regulatory approval. The company reported a net loss of $26.2 million for Q2 2025 (GAAP), deeper than the prior year’s loss, and a GAAP earnings per share figure of ($0.40). Revenue (GAAP) was zero, as widely expected for a clinical-stage biotech. Overall, the period underscored the risks and potential facing the company, with regulatory timing and funding runway now in sharper focus. Source: Analyst estimates for the quarter provided by FactSet. Io Biotech is developing immunotherapy treatments to help the body's immune system fight cancer. Its core technology, the T-win® platform, is designed to produce cancer vaccines that target cells within the tumor microenvironment. These vaccines aim to activate T cells—an important part of the immune system—to attack both tumor cells and suppressive immune cells that allow cancer to grow unchecked.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool